Pevonedistat
Pevonedistat is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary myelofibrosis | D055728 | D47.4 | 2 | 1 | — | — | — | 2 | |
| Non-small-cell lung carcinoma | D002289 | — | 2 | — | — | — | 2 | ||
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 2 | 1 | — | — | — | 2 | |
| Residual neoplasm | D018365 | — | 1 | — | — | — | 1 | ||
| Essential thrombocythemia | D013920 | D47.3 | 1 | 1 | — | — | — | 1 | |
| Polycythemia vera | D011087 | D45 | 1 | 1 | — | — | — | 1 | |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | C92.2 | 1 | 1 | — | — | — | 1 | |
| Neutrophilic leukemia chronic | D015467 | D47.1 | 1 | 1 | — | — | — | 1 | |
| Eyelid neoplasms | D005142 | EFO_1000934 | 1 | 1 | — | — | — | 1 | |
| Thrombocytosis | D013922 | D75.83 | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 4 | — | — | — | — | 4 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | — | — | — | — | 2 | |
| Multiple myeloma | D009101 | C90.0 | 2 | — | — | — | — | 2 | |
| Lymphoma | D008223 | C85.9 | 2 | — | — | — | — | 2 | |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEVONEDISTAT |
| INN | pevonedistat |
| Description | Pevonedistat is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes. It has a role as an apoptosis inducer and an antineoplastic agent. It is a pyrrolopyrimidine, a secondary amino compound, a member of cyclopentanols, a sulfamidate and a member of indanes. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 905579-51-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1231160 |
| ChEBI ID | — |
| PubChem CID | 16720766 |
| DrugBank | DB11759 |
| UNII ID | S3AZD8D215 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 835 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
227 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more